Detalhe da pesquisa
1.
Dabrafenib plus trametinib in patients with relapsed/refractory BRAF V600E mutation-positive hairy cell leukemia.
Blood
; 141(9): 996-1006, 2023 03 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36108341
2.
Olaparib maintenance versus placebo in platinum-sensitive non-small cell lung cancer: the Phase 2 randomized PIPSeN trial.
Br J Cancer
; 130(3): 417-424, 2024 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-38097741
3.
Sequence analyses of relapsed or refractory diffuse large B-cell lymphomas unravel three genetic subgroups of patients and the GNA13 mutant as poor prognostic biomarker, results of LNH-EP1 study.
Am J Hematol
; 98(4): 645-657, 2023 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-36606708
4.
Dabrafenib plus trametinib in patients with BRAFV600E-mutant low-grade and high-grade glioma (ROAR): a multicentre, open-label, single-arm, phase 2, basket trial.
Lancet Oncol
; 23(1): 53-64, 2022 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34838156
5.
First-in-human phase 1 study of budigalimab, an anti-PD-1 inhibitor, in patients with non-small cell lung cancer and head and neck squamous cell carcinoma.
Cancer Immunol Immunother
; 71(2): 417-431, 2022 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-34216247
6.
Patterns of progression in patients treated for immuno-oncology antibodies combination.
Cancer Immunol Immunother
; 70(1): 221-232, 2021 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-32700090
7.
Association of metastatic pattern and molecular status in stage IV non-small cell lung cancer adenocarcinoma.
Eur Radiol
; 30(9): 5021-5028, 2020 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-32323012
8.
A phase Ib dose-finding, pharmacokinetic study of the focal adhesion kinase inhibitor GSK2256098 and trametinib in patients with advanced solid tumours.
Br J Cancer
; 120(10): 975-981, 2019 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-30992546
9.
Phase I trial of bortezomib daily dose: safety, pharmacokinetic profile, biological effects and early clinical evaluation in patients with advanced solid tumors.
Invest New Drugs
; 36(4): 619-628, 2018 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-29094232
10.
Outcomes and prognostic factors for relapsed or refractory lymphoma patients in phase I clinical trials.
Invest New Drugs
; 36(1): 62-74, 2018 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-28597151
11.
Predictive factors of renal toxicities related to anti-VEGFR multikinase inhibitors in phase 1 trials.
Invest New Drugs
; 35(1): 79-86, 2017 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-27783256
12.
Prognostic factors and outcome of patients with hematological malignancies in phase I trials: the Gustave Roussy scoring system.
Anticancer Drugs
; 28(5): 540-545, 2017 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-28225458
13.
Patients aged over 75 years enrolled in Phase I clinical trials: the Gustave Roussy experience.
Int J Cancer
; 138(4): 875-80, 2016 Feb 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-26370299
14.
A never-smoker lung adenocarcinoma patient with a MET exon 14 mutation (D1028N) and a rapid partial response after crizotinib.
Invest New Drugs
; 34(3): 397-8, 2016 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-26892698
15.
Innovative therapies based on molecular orientation in patients with relapse and refractory diffuse large B-cell lymphoma: Results of LNH-EP1 study.
Am J Hematol
; 96(10): E376-E379, 2021 10 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34165816
16.
Phase I study of afatinib combined with nintedanib in patients with advanced solid tumours.
Br J Cancer
; 113(10): 1413-20, 2015 Nov 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-26512876
17.
Reactions and adverse events induced by T-cell engagers as anti-cancer immunotherapies, a comprehensive review.
Eur J Cancer
; 205: 114075, 2024 May 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-38733717
18.
Antibody drug conjugates in older patients: State of the art.
Crit Rev Oncol Hematol
; 193: 104212, 2024 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-38007063
19.
TROP-2 directed antibody-drug conjugates (ADCs): The revolution of smart drug delivery in advanced non-small cell lung cancer (NSCLC).
Cancer Treat Rev
; 118: 102572, 2023 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-37230055
20.
Tusamitamab Ravtansine in Patients with Advanced Solid Tumors: Phase I Study of Safety, Pharmacokinetics, and Antitumor Activity Using Alternative Dosing Regimens.
Cancer Res Commun
; 3(8): 1662-1671, 2023 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-37645622